The Trump administration’s crackdown on fraud, waste and abuse continues, with the Department of Justice last week launching a new effort targeting healthcare fraud. Experts think the new strike force ...

Disagreements between providers and payers have been moving into the courtroom over the past few weeks. The California ...

GoodRx, a prescription savings platform, introduced GoodRx Employer Direct on Tuesday, an offering that allows employers to lower the cost of certain brand medications like GLP-1s. Santa Monica, ...

Rosarium Health, a company enabling aging at home, has raised $6 million in seed funding and secured partnerships with several Medicaid and Medicare Advantage plans, the company shared with MedCity ...

When a biotech startup reveals a substantial round of funding, the announcement typically includes information about a pipeline, or at least a lead drug candidate. Large sums are also often a sign of ...

Capstan’s initial focus is the development of in vivo chimeric antigen receptor, or CAR T, therapies. CAR T-drugs are currently made from a patient’s own T cells, which are engineered in a lab before ...

Social comments show how patients, caregivers, and HCPs interpret your content in real time. They reveal where questions keep surfacing, where misinformation starts to take hold, and how people ...

AstraZeneca is expanding its prospects in cardiometabolic disease, paying $1.2 billion to begin a partnership on eight programs that include obesity drug candidates with potential advantages over ...

Critical care transport is one of the most intense and demanding parts of emergency medical services. We’re talking about patients in the most fragile situations: premature newborns, trauma victims, ...

Angelini Pharma is acquiring Catalyst Pharmaceuticals in a $4.1 billion deal that gives the Italy-based brain medicines company three commercialized rare disease products and entry into the U.S.

Patients who switched from weekly to monthly maintenance dosing of an experimental Pfizer obesity drug achieved an average placebo-adjusted weight loss of up to 12.3% in a mid-stage study, results ...

Severe asthma is already treatable with a monthly injectable GSK drug, the blockbuster product Nucala. A new FDA approval gives the drugmaker the opportunity to reach patients with a different ...